We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Pharmacovigilance – News and Features

News

Galapagos Initiates Second Phase I Clinical Trial for GLPG0259

The new trial is based on the positive outcome of the first-in-human trial conducted earlier in 2009.
News

Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101

The 75-patient Phase II clinical study to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.
News

NanGenex Announce Global Launch of NanoActive

“The NanoActive™ technology provides nanoformulation solutions for original as well as generic applications.
News

Rise in Weight-Loss Drugs Prescribed to Combat Childhood Obesity

New study focuses on prescriptions in the UK, where the drugs are not licensed for use under the age of 18.
News

DHR to Acquire Life Sciences Instrumentation Businesses from MDS Inc. and Life Technologies Corp

Danaher will now own outright AB SCIEX and Molecular Devices for the combined transactions of $1.1 billion.
News

New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patients

GlycoMimetics’ GMI-1070 targets vaso-occlusive crisis by inhibiting the inflammatory processes underlying cell adhesion.
News

German Biosafety Committee statement on Bt Maize

Scientific arguments used in the German safeguard clause on MON810 (English translation). The ZKBS states that the cultivation of MON810 has no adverse effect on the environment.
News

ACADIA Announces Results from Phase III Trial of Pimavanserin in Parkinson’s Disease Psychosis

Pimavanserin misses primary endpoint of antipsychotic efficacy; meets key secondary endpoint of motoric tolerability.
News

UK Leads European Research Programme with £10M Investment in Bioscience Data Handling Capacity

The UK has made its first substantial commitment to a major emerging pan-European science project with a £10M investment.
News

New Biomarker Predicts Response to Hepatitis C Treatment

Newly identified genetic marker that predicts response to hepatitis C treatments may also explain difference in rates of response among racial and ethnic groups.
Advertisement